Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb reported Q3 revenue of $1.375 billion, up 8% on a constant-currency basis, and adjusted EBITDA of $325 million, up 34%; adjusted EBITDA margin expanded 460 basis points to 23.6%. The company raised full-year 2026 revenue guidance to $5.450 billion–$5.550 billion and adjusted EBITDA guidance to $1.090 billion–$1.140 billion, with the midpoint implying a 20.3% margin. Net leverage fell to 4.1x from 5.7x a year earlier; results included a one-time $14 million tariff refund, while gross margin excluding it was 63.6%.

Analysis

BLCO’s key read-through is earnings quality, not simply the beat: underlying gross-margin improvement remains meaningful after removing the one-time tariff benefit, while premium mix and cost actions can compound if growth persists. That makes the quarter more than a one-off margin event—but the market should not annualize Q3’s margin or EBITDA growth. The full-year margin outlook is the more appropriate near-term anchor.

The equity’s risk profile is improving as cash conversion pays down debt, but leverage remains high enough that execution matters: weaker growth or a reversal in margin gains would limit flexibility and keep interest expense a material drag. An interim CEO focused on profitability may accelerate cost discipline; the counter-risk is that portfolio-gap acquisitions compete with debt reduction before the balance sheet is safer. Any M&A rationale should be tested against return on invested capital and leverage impact, not pipeline rhetoric.

Over the next 1–3 months, watch Q4 execution, the tariff-adjusted margin run rate, and whether strong prescription/contact-lens demand holds. Over 6–18 months, premium IOL adoption and new-product/pipeline milestones offer upside, but remain execution- and approval-dependent. Miebo’s growth is volume-led, which is encouraging; persistence in prescriptions is more informative than reported sales alone. The contrarian point: strong headline growth may obscure a less exciting baseline once the tariff refund and unusually favorable mix are stripped out. There is no clear earnings read-through to NVST from this call; do not treat its mention as evidence of a commercial linkage.

Key Decisions for Investors

• BLCO: Favor a measured long/add on post-earnings consolidation rather than chasing the initial reaction. The thesis is continued mix-led margin expansion plus debt reduction; valuation and price levels were not provided, so size against your own risk limits.
• Verify the 10-Q and subsequent quarter for adjusted gross margin excluding one-offs, free-cash-flow conversion, and net leverage progress toward management’s target. A stalled leverage decline or weaker cash conversion would weaken the equity case.
• Track Miebo prescription trends and daily SiHy/premium IOL growth into the next report. Decelerating demand alongside any guidance reduction would falsify the durable-growth thesis; pipeline milestones should remain upside options, not base-case earnings.
• Watch for acquisitions: require evidence of credible returns and limited interference with deleveraging before giving M&A announcements a positive read-through. No separate NVST trade is indicated by this call.